Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 12/20 | 0.50 |
| ▸ | CA2 | P00918 | 12/20 | 0.50 |
| ▸ | CA9 | Q16790 | 8/20 | 0.43 |
| ▸ | CA12 | O43570 | 4/20 | 0.42 |
| ▸ | CA7 | P43166 | 4/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.42 |
| ▸ | CA3 | P07451 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA6 | P23280 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28421490 | 0.92 | CA1 (0.53) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9403962 | 0.92 | CA1 (0.53) | CA1CA2CA9CA12CA7 | |
| SCHEMBL28421390 | 0.92 | CA1 (0.53) | CA1CA2CA9CA12CA7 | |
| SCHEMBL11049951 | 0.90 | CA1 (0.52) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9980923 | 0.86 | CA1 (0.46) | CA1CA2CA9CA12CA7 | |
| Ether SCHEMBL22975446 | 0.84 | CA1 (0.46) | CA1CA2CA9CA12CA7 | |
| SCHEMBL9980748 | 0.83 | CA1 (0.47) | CA1CA2CA9CA12CA7 | |
| SCHEMBL16108599 | 0.81 | CA1 (0.64) | CA1CA2CA9CA12CA7 | |
| SCHEMBL19733 | 0.81 | CA1 (0.64) | CA1CA2CA9CA12CA7 | |
| SCHEMBL28123592 | 0.81 | CA1 (0.64) | CA1CA2CA9CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| WO-2022081594-A1 | ANTIMICROBIAL COMBINATION THERAPEUTICS | AEQUOR, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3984540-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE | Aequor, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
| US-8460821-B2 | Non-aqueous electrolyte secondary battery, non-aqueous electrolyte, and method for fabricating non-aqueous electrolyte secondary battery | GS YUASA INTERNATIONAL LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-20110318655-A1 | NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY, NON-AQUEOUS ELECTROLYTE, AND METHOD FOR FABRICATNG NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY | GS YUASA INTERNATIONAL LTD. (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | CA1 3715/4885CA2 2294/4885CA9 2546/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | CA1 2715/4885CA2 738/4885CA9 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.